Arthrosi Therapeutics has filed a notice of an exempt offering of securities to raise $20,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Arthrosi Therapeutics is raising $20,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Litain Yeh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Arthrosi Therapeutics
Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018, by a world-class team of gout experts who spearheaded the clinical development of the first generation of urate inhibitor treatment for gout at Ardea Biosciences resulting in a $1.26 Billion acquisition by AstraZeneca. With its vast therapeutic and treatment knowledge, Arthrosi has efficiently completed multiple robust phase 1 and 2 clinical studies in a mere two years and accumulated a comprehensive and robust intellectual property portfolio. Our proprietary molecule, AR882, is designed to lower uric acid, diminish tophi, and reduce gout flares without renal safety issues. The new molecule has shown unmatched promise, with industry-leading efficacy rates and superior safety profiles in Phase 1 and 2 trials.
To learn more about Arthrosi Therapeutics, visit http://arthrosi.com/
Contact:
Litain Yeh, Chief Executive Officer
714-813-0709
https://www.linkedin.com/in/litain-yeh-58b8575/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.